Overview

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bioverativ - a sanofi company
Bioverativ, a Sanofi company

Treatments:

Busulfan
JM 3100
Plerixafor